Aydah AlAwadhi, MD 🇦🇪· @Aydah_AlAwadhi · X·· 12 小时前评分70
正文 · 原文
Well-deserved standing ovation! The Phase 3 DeLLphi-305 trial showed that adding tarlatamab-dlle to durvalumab maintenance therapy significantly improved OS in lung cancer (ES-SCLC) patients without progression after initial chemoimmunotherapy. @myESMO @OncoAlert #bcsm #ESMO26
122 浏览 · 1 赞 · 1 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Aydah AlAwadhi, MD 🇦🇪 · x.com